ArticleBMC infectious diseases2026
Breakthrough serogroup Y meningococcal disease in a vaccinated patient with myasthenia gravis receiving ravulizumab: a case report.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a case of fulminant invasive meningococcal disease caused by Neisseria meningitidis serogroup Y in a young, immunocompromised adult with myasthenia gravis receiving long-term immunosuppressive therapy including ravulizumab, despite prior meningococcal vaccination. Serogroup Y is increasingly recognized in epidemiological surveillance and may be associated with atypical clinical manifestations, including the uncommon coexistence of meningitis and pulmonary involvement, as observed in this patient. The illness was characterized by rapid progression to septic shock, meningitis, and presumed pleuropneumonia. Diagnosis was confirmed by both blood PCR and culture. This case highlights the increased susceptibility to invasive meningococcal infections in individuals receiving complement-inhibiting therapy and underscores the importance of comprehensive preventive strategies, including a carefully planned and implemented vaccination schedule and careful individualized consideration of antimicrobial prophylaxis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.